Agenus Inc.

AGEN

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001098972

E

weakest fifth of 305 graded peers in healthcare

rank 299 of 305; percentile 98.0; sampling error 2.8 points; lower is stronger

A B C D E

E, the bear



Scoreboard	
Profitability	C/D percentile 61.5
Solvency	E percentile 96.4
Growth and financing	D percentile 72.2
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $226.8M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution not computable: distress
Inputs computable	7 of 13
Graded from	filings received through Mar 16, 2026 252 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$5.96 2026-11-20; market equity $269.9M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 16, 2026

Even if we obtain regulatory approval to market our product candidates, the availability and price of our competitors' products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 61.5						
Gross profitability	49.9%	32.8%		24.1	346	2025-12-31
Return on invested capital	not computable	9.6%				
average invested capital must exceed $1,000,000						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	32.7%	(6.7%)	96.8	756	2025-12-31
Gross margin stability, five years	3.9 pts	2.8 pts	63.6	237	2025-12-31
Solvency, sleeve percentile 96.4					
Altman Z double-prime	not computable	0.31			
one or more required annual facts are missing					
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(3.61x)			
latest aligned inputs end 2014-12-31; latest annual assets end 2025-12-31					
Current ratio	0.41x	2.68x	96.4	781	2025-12-31
Growth and financing, sleeve percentile 72.2					
Revenue growth, three-year compound	5.2%	9.6%	59.1	400	2025-12-31
Free cash flow growth, three-year compound	not computable	11.1%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	33.9%			
NOPAT must exceed $100,000					
Asset growth, three years	(18.1%)	3.2%	81.4	663	2025-12-31
Net share issuance, one year	51.7%	1.6%	76.2	626	2026-03-12

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 51.7%

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
294	Dare Bioscience, Inc. (DARE)	96.4	E	dilution
295	Longeveron Inc. (LGVN)	96.7	E	short runway
296	ALX Oncology Holdings Inc. (ALXO)	97.0	E	dilution, degenerate inputs, fortress balance sheet
297	Clene Inc. (CLNN)	97.4	E	dilution, distress
298	Nektar Therapeutics (NKTR)	97.7	E	dilution, short runway
299	Agenus Inc. (AGEN)	98.0	E	dilution
300	Vyome Holdings, Inc. (HIND)	98.4	E	dilution, late filer, fortress balance sheet
301	Sintx Technologies, Inc. (SINT)	98.7	E	dilution, short runway
302	Atara Biotherapeutics, Inc. (ATRA)	99.0	E	dilution, short runway, distress
303	Coherus Oncology, Inc. (CHRS)	99.3	E	dilution, short runway
304	HCW Biologics Inc. (HCWB)	99.7	E	dilution, short runway, late filer, degenerate inputs, fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	150.1%	(1.7%)	97
Distance from 52-week high	(39.9%)	(33.0%)	43
EBIT to enterprise value	(8.7%)	0.5%	31
Free cash flow yield	(28.6%)	0.6%	18
Book value to price	(0.39)	0.29	3
Sales to price	0.42	0.38	54
Composite equity issuance, five years	146.8%	13.5%	87
Relative strength against the sector, log excess return	0.75	(0.19)	97
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 4 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$66.9M
Operating cash flow, four quarters	-$103.9M
Months of runway	7.7
Days since last periodic filing	18 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$5.5M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$114.2M	2025-12-31	2026-03-16	10-K	26-108632
2	cost of revenue	us-gaap:CostOfRevenue	$1.0M	2025-12-31	2026-03-16	10-K	26-108632
3	assets	us-gaap:Assets	$226.8M	2025-12-31	2026-03-16	10-K	26-108632
4	operating income	us-gaap:OperatingIncomeLoss	-$20.2M	2025-12-31	2026-03-16	10-K	26-108632
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$3.1M	2025-12-31	2026-03-16	10-K	26-108632
6	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2025-12-31	2026-03-16	10-K	26-108632
7	total debt	us-gaap:LongTermDebt	$44.7M	2025-12-31	2026-03-16	10-K	26-108632
8	book equity	us-gaap:StockholdersEquity	-$271.1M	2025-12-31	2026-03-16	10-K	26-108632
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$3.0M	2025-12-31	2026-03-16	10-K	26-108632
10	total debt	us-gaap:LongTermDebt	$33.2M	2024-12-31	2026-03-16	10-K	26-108632
11	book equity	us-gaap:StockholdersEquity	-$326.4M	2024-12-31	2026-03-16	10-K	26-108632
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$40.4M	2024-12-31	2026-03-16	10-K	26-108632
13	net income	us-gaap:ProfitLoss	-$3.1M	2025-12-31	2026-03-16	10-K	26-108632
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$77.2M	2025-12-31	2026-03-16	10-K	26-108632
15	assets	us-gaap:Assets	$226.3M	2024-12-31	2026-03-16	10-K	26-108632
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$103.5M	2024-12-31	2026-03-16	10-K	26-108632
17	cost of revenue	us-gaap:CostOfRevenue	$486,000	2024-12-31	2026-03-16	10-K	26-108632

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$156.3M	2023-12-31	2026-03-16	10-K	26-108632
19	cost of revenue	us-gaap:CostOfRevenue	$3.1M	2023-12-31	2026-03-16	10-K	26-108632
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$98.0M	2022-12-31	2025-03-17	10-K	25-040289
21	cost of revenue	us-gaap:CostOfRevenue	$10.6M	2022-12-31	2025-03-17	10-K	25-040289
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$295.7M	2021-12-31	2024-03-14	10-K	24-031620
23	cost of revenue	us-gaap:CostOfRevenue	$3.5M	2021-12-31	2024-03-14	10-K	24-031620
24	depreciation amortization	us-gaap:Depreciation	$9.7M	2025-12-31	2026-03-16	10-K	26-108632
25	operating income	us-gaap:OperatingIncomeLoss	-$43.3M	2014-12-31	2017-03-16	10-K	17-004618
26	interest expense	us-gaap:InterestExpense	$1.3M	2014-12-31	2015-03-16	10-K	15-001809
27	current assets	us-gaap:AssetsCurrent	$133.4M	2025-12-31	2026-03-16	10-K	26-108632
28	current liabilities	us-gaap:LiabilitiesCurrent	$323.5M	2025-12-31	2026-03-16	10-K	26-108632
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$6,000	2025-12-31	2026-03-16	10-K	26-108632
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$158.3M	2024-12-31	2026-03-16	10-K	26-108632
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$576,000	2024-12-31	2026-03-16	10-K	26-108632
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$224.2M	2023-12-31	2026-03-16	10-K	26-108632
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$10.0M	2023-12-31	2026-03-16	10-K	26-108632
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$175.4M	2022-12-31	2025-03-17	10-K	25-040289
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$53.1M	2022-12-31	2025-03-17	10-K	25-040289
36	current assets	us-gaap:AssetsCurrent	$45.6M	2024-12-31	2026-03-16	10-K	26-108632
37	current liabilities	us-gaap:LiabilitiesCurrent	$221.4M	2024-12-31	2026-03-16	10-K	26-108632
38	assets	us-gaap:Assets	$313.9M	2023-12-31	2025-03-17	10-K	25-040289
39	assets	us-gaap:Assets	$413.6M	2022-12-31	2024-03-14	10-K	24-031620
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	38,398,354	2026-03-12	2026-03-16	10-K	26-108632
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	25,308,841	2025-03-13	2025-03-17	10-K	25-040289

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.